id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-329741-604gtqx9	Tombetti, Enrico	Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020	2020-06-19		.txt	text/plain	5745	295	38	Here, we review current pharmacological management of IRP-with a specific focus on recent advances represented by the advent of anti-IL1 agents in the field-and of specific clinical settings including pediatric or pregnant patients and RP secondary to post-cardiac injury, systemic autoimmune, or autoinflammatory diseases. First-line therapy of recurrences of IRP treatment does not differ from that for the first episode of acute idiopathic pericarditis, although it should be tapered more slowly: high-dose acetylsalicylic acid (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are the mainstays of therapy [1••] . Given anakinra safety and efficacy in children with autoinflammatory diseases and in pediatric case series of refractory IRP [39, 59•, 60] , it might be rational to use anakinra earlier than in adult patients (e.g., as a second-line therapy or after a lower number or relapses). Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial	./cache/cord-329741-604gtqx9.txt	./txt/cord-329741-604gtqx9.txt